Doctors upset over Intuitive system's lack of interoperability, TheStreet says The doctors and hospitals "expected to pay for and use" the new da Vinci Xi systems recently launched by Intuitive Surgical are upset over the way the launch was handled and the fact that the new system does not work with their existing prior generation da Vinci robots, said Benjamin Davies, MD, in a report published by TheStreet. Reference Link
Intuitive Surgical initiated with a Neutral at Piper Jaffray Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.